Company: PIII
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001140361-25-016302
Chunk: 44

Company: P3 Health Partners Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 44
---
 through the date of termination, Dr. Coffman’s estate will be entitled to receive a pro-rated portion of his target bonus for the year of termination. The CEO Employment Agreement includes customary confidentiality and mutual non-disparagement provisions, as well as a standard non-compete restriction effective during employment and for 18 months thereafter and service provider/customer non-solicitation restrictions effective during employment and for 24 months thereafter. Sherif Abdou, M.D. Consulting Agreement In connection with Dr. Abdou’s resignation as Chief Executive Officer and President of the Company on May 8, 2024, we entered into a Consulting Agreement (the “Abdou Consulting Agreement”) with him, pursuant to which Dr. Abdou has continued to provide services to the Company as a consultant (as contemplated by Dr. Abdou’s Executive Employment Agreement, executed as of May 15, 2022). The term of the consulting arrangement commenced on May 8, 2024 and ends on April 30, 2025, unless terminated earlier in accordance with the Abdou Consulting Agreement.

28

TABLE OF CONTENTS During the consulting period, Dr. Abdou has served as a Senior Advisor to the Board and the Chief Executive Officer, and provided services with respect to the business and operations of the Company. Dr. Abdou received an aggregate consulting fee of $400,000, which was paid in six substantially equal installments in May through October 2024. The agreement and consulting relationship may be terminated by either party after providing at least 30 days’ written notice to the other party. If the agreement and the consulting relationship is terminated prior to April 30, 2025, then the Company will pay to Dr. Abdou any earned but unpaid consulting fee. Amir Bacchus, M.D. Employment Agreement We entered into an employment agreement with Dr. Bacchus (the “Bacchus Employment Agreement”) in May 2022, which superseded his earlier employment agreement. The initial term of the Bacchus Employment Agreement ended on January 1, 2025, and the term automatically will renew for successive one-year terms unless advance written notice of non-renewal is given by either party. In addition, during the employment term, for so long as Dr. Bacchus serves as Chief Medical Officer, the Company will nominate Dr. Bacchus for re-election as a member of the Board. The Bacchus Employment Agreement provides for a base salary of $600,000 and eligibility to earn an annual